Welcome to our dedicated page for Sigyn Therapeutics news (Ticker: SIGY), a resource for investors and traders seeking the latest updates and insights on Sigyn Therapeutics stock.
Sigyn Therapeutics, Inc. (SIGY) is a development-stage medical technology company whose news flow centers on its dialysis-like blood purification therapies and related corporate developments. Company announcements highlight progress on Sigyn Therapy, a novel blood purification technology aimed at pathogen-associated inflammatory disorders, as well as its oncology-focused platforms ImmunePrep, ChemoPrep, and ChemoPure.
News releases frequently cover clinical and regulatory milestones, such as plans for first-in-human feasibility studies of Sigyn Therapy in end-stage renal disease patients with endotoxemia and concurrent inflammation, drafting of an Investigational Device Exemption for submission to the U.S. Food and Drug Administration, and discussions of potential Breakthrough Device submissions. Investors can also find updates on annual and quarterly financial results, including the filing of Form 10-K and other SEC reports referenced in company communications.
Sigyn Therapeutics also issues news about capital markets and corporate actions, including its 1-for-40 reverse stock split and efforts to meet listing requirements for The Nasdaq Capital Market. Coverage includes participation in emerging growth and small-cap conferences, such as the Emerging Growth Conference and LD Micro Main Event, where management presents updates on the companys therapeutic pipeline and development plans.
In addition, third-party research coverage, such as reports from Goldman Small Cap Research, is sometimes summarized in press releases that describe Sigyn Therapeutics as a developer of next-generation blood purification therapies for life-threatening conditions without FDA-approved treatments. For investors and observers, the SIGY news feed offers a consolidated view of clinical planning, technology development, financing steps, and investor outreach activities related to the companys blood purification and oncology-support platforms.
Sigyn Therapeutics (OTCQB: SIGY) announced the filing of trademark applications for ChemoPrep and ChemoPure with the USPTO, linked to a patent for enhancing chemotherapy delivery while reducing toxicity. The new system aims to improve tumor site delivery and minimize side effects of chemotherapeutic agents, addressing significant challenges in cancer treatment. Sigyn's technology may also inhibit cancer metastasis related to chemotherapy. The company continues to develop its pipeline, including Sigyn Therapy, targeting unmet health needs.
Sigyn Therapeutics (OTCQB: SIGY) has filed a provisional patent application for a system to enhance chemotherapy delivery and reduce associated toxicity. Currently, less than 5% of chemotherapeutic agents effectively reach tumor sites, leading to toxic side effects and drug resistance. The proposed system aims to improve drug delivery while potentially reducing treatment dosages. CEO Jim Joyce emphasized that this innovation is designed to enhance existing FDA-approved drugs. The company is also advancing its Sigyn Therapy for patients with end-stage renal disease and other serious conditions.
Sigyn Therapeutics (OTCQB: SIGY) has appointed Richa Nand, Jim Dorst, and Christopher Wetzel to its Board of Directors, effective October 10, 2022. This move aims to enhance the company's leadership as it progresses in its clinical development. Nand brings over 20 years of experience in intellectual property law, Dorst has a robust background in finance and operations, while Wetzel holds extensive leadership experience in healthcare delivery. These appointments are expected to bolster Sigyn's strategy in advancing its Sigyn Therapy, which targets pathogen-associated inflammatory disorders.
Sigyn Therapeutics (OTCQB: SIGY) plans to pursue first-in-human feasibility studies of Sigyn Therapy for End-Stage Renal Disease (ESRD) patients experiencing inflammation and endotoxemia. As more than 550,000 individuals in the U.S. suffer from ESRD, and no approved drugs exist for related inflammation, this therapy aims to improve patient outcomes. The therapy combines with regular dialysis to target inflammation by extracting pathogens and cytokines from the bloodstream. The company is updating an Investigational Device Exemption for FDA submission, though success is not guaranteed.
Sigyn Therapeutics, Inc. (OTCQB: SIGY) reported its Q2 2022 financial results, showing a net loss of approximately $666,000, or $0.02 per share. This compares to a net loss of $650,000 in Q2 2021. The company announced the successful completion of in vivo animal studies for its Sigyn Therapy, aimed at treating life-threatening infections and inflammatory disorders. Additionally, it appointed Jeremy Ferrell as CFO and established a Scientific Advisory Board. Sigyn's stock graduated to the OTCQB Venture Exchange, and it continues pursuing a major exchange listing.
Sigyn Therapeutics, Inc. (OTCQB: SIGY) has commenced trading on the OTCQB® Venture Exchange, moving from the OTC Pink Market. This transition aligns with the company's goal of listing on a major exchange. Sigyn Therapeutics is advancing Sigyn Therapy™, a blood purification technology designed to extract infectious pathogens and inflammatory mediators. The technology targets conditions such as sepsis and end-stage renal disease. CEO Jim Joyce emphasized the significance of this development as part of the company's evolution.
Sigyn Therapeutics (OTC: SIGY) has appointed Dr. Donald J. Hillebrand to its Scientific Advisory Board. Dr. Hillebrand is a leading expert in Hepatology and Liver Transplantation. His background includes significant clinical research and contributions to medical literature. Sigyn specializes in treating conditions related to sepsis, utilizing their innovative Sigyn Therapy™ for blood purification that targets pathogen-related inflammation. The company emphasizes the importance of their therapy in addressing severe infectious diseases and liver disorders.
Sigyn Therapeutics, Inc. (OTC Markets: SIGY) announced the appointment of Dr. Ajay Verma to its Scientific Advisory Board. Dr. Verma, a notable figure in neurology, brings extensive clinical experience that is expected to enhance the development of Sigyn Therapy, an extracorporeal blood purification technology aimed at treating life-threatening inflammatory disorders. His previous roles include leading R&D at Yumanity Therapeutics and serving at prominent companies like Biogen and Novartis. Sigyn Therapeutics focuses on addressing sepsis and other severe conditions through innovative medical technology.
Sigyn Therapeutics (OTC: SIGY) has filed its annual report for the year ended December 31, 2021, highlighting significant advancements in its Sigyn Therapy, a blood purification technology aimed at treating sepsis and inflammatory disorders. The company reported an operating loss of approximately $2.0 million, up from $916,000 in 2020. Additionally, it showcased various milestones, including successful studies demonstrating the therapy's effectiveness against viral pathogens and hepatic toxins. Sigyn plans to submit an Investigational Device Exemption to the FDA for clinical studies, indicating a commitment to advancing its innovative treatment.
Sigyn Therapeutics (SIGY) appointed Dr. H. David Humes, a recognized nephrologist, to its Scientific Advisory Board. Dr. Humes brings extensive expertise in medical technology, especially in overseeing preclinical studies of Sigyn Therapy, a blood purification technology aimed at treating sepsis and related conditions. His contributions are expected to enhance clinical advancements for the therapy, which targets life-threatening inflammatory disorders. With a strong academic background and numerous patents, Dr. Humes is well-positioned to support Sigyn's mission to combat sepsis and other serious health threats.